Karyopharm hits record low after endometrial cancer trial miss
KPTI•Company shifts focus to other programs
Karyopharm said it will reduce investment in endometrial cancer and focus more on its myelofibrosis and multiple myeloma programs.
The stock was set for its worst trading day on record if losses held.
Including the session's moves, the stock was down 73% year to date.
Shares sink to all-time low after late-stage trial miss
Shares of Karyopharm Therapeutics KPTI.O fell 71.9% to an all-time low of $1.97.
The stock fell below its previous 52-week low of $3.65 set in August 2025.
The company said late on Thursday its drug selinexor as a maintenance therapy for advanced or recurrent endometrial cancer missed its main goal of significantly improving progression-free survival in a late-stage trial.
Patients on selinexor lived a median 12.75 months without disease progression versus 7.43 months on placebo, but the difference was not statistically significant, the company said.
